Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-line Treatment of KRAS-mutant Metastatic Colorectal Cancer: A Phase 1b Clinical Study.
Daniel H AhnAfsaneh BarziMaya RidingerErrin SamuëlszRamanand A SubramanianPeter J P CroucherTod SmealFairooz F KabbinavarHeinz-Josef LenzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Onvansertib combined with FOLIFRI/bevacizumab exhibited manageable safety and promising efficacy in second-line treatment of KRAS-mutant metastatic CRC patients. Further exploration of this combination therapy is ongoing.